Exceptional Outcomes Observed With the "Next Generation" PRESILLION(TM) Plus (PioNIR(TM) ) Bare Metal Stent Systems From the PioNIR(TM) Study at 9 and 12-Months Follow-up in the Treatment of Stenotic Coronary Artery Lesions

Clinically Driven Target Lesion Revascularization (TLR) of 6.3% at One Year

PARIS, May 18, 2011 - One-year results from the 278-patient multi-center, prospective,
single-arm study conducted at 16 sites in Europe and Israel were presented
today at the EuroPCR 2011 Congress in Paris. These results reinforce the
exceptional outcomes observed with the "Next Generation" PRESILLION(TM) Plus
(PioNIR(TM)) cobalt chromium bare metal stent systems at 9-month follow-up,
which was the primary endpoint of the PioNIR(TM) study.

The PRESILLION Plus features important technological advances designed to
help restore the artery's natural form, support it to minimize the
probability of restenosis and ensure easier access to distal lesions.

The data were presented by Dr. Stefan Hoffmann, Vivantes Klinikum im
Friedrichshain, Berlin, Germany, during the EuroPCR session on registries of
new generation bare metal stents.

Target Lesion Revascularization (TLR) at one year was 6.3% and Target
Vessel Revascularization (TVR) was 8.1% at one year post procedure. A total
of 278 patients were enrolled with a mean age of 65.5 years, 20.5% were
diabetic, 27.8% had a history of MI, and 36.2% had a history of previous
percutaneous coronary intervention. Device success was achieved in 98.2% of
patients. The primary endpoint of TVF defined as cardiac death, target vessel
myocardial infarction (MI), or clinically driven target vessel
revascularization (TVR) within 270 days post procedure was 8.9% at 9 months,
substantially less than the 16.46% performance goal derived using a
meta-analysis of the standard-of-care therapy, coronary stenting with bare
metal stents. Target vessel MI was 3.3% at one year post procedure. The
overall rate of stent thrombosis was 0.7% at discharge and 1.1% up to one
year post procedure. There was no stent thrombosis observed after 30 days.
The PIONIR study was conducted to support a PMA in the US.

Dr. Hoffmann :" Presillion Plus is a new generation BMS with unique
design and engineering capacities allowing good deliverability, vessel
conformability and superior scaffolding."

PRESILLION(TM) Plus is the only stent in the market with an adaptive
closed cell design that is capable of differential cell lengthening. This
enables the stent to be flexible in the unexpanded configuration, and
optimally support the vessel while conforming to the natural curve of the
vessel in the expanded configuration.

"The unique geometry of the Presillion(tm) combines alternating rings
optimizing both the flexibility and conformability on one hand, with
continuous scaffolding on the other, like no other stent in the market. The
new delivery system includes a hypo-tube for improved pushability in crossing
calcified and other "stubborn" lesions and a redesigned semi-compliant
balloon for precise stent deployment, higher rated burst pressure and
decreased deflation time" says Dr. Kobi Richter, chairman of the board and
Chief Technology Officer for Medinol.

The outstanding results of the PioNIR(TM) study may widen the domain of
BMS use and suggest a more cost effective use of BMS in borderline cases,
without the risk of thrombosis or extended dual anti-platelet therapy.

The PRESILLION(TM) Plus stent is approved in more than 100 countries
worldwide.

The product is not yet available in the US market and is pending PMA
approval.

The Presillion and Presillion Plus stent systems are designed developed
and manufactured by Medinol Ltd, Israel. Medinol is a stent innovation
company that develops both stents and delivery systems through design
innovation and advanced manufacturing technologies.

PioNIR(TM) is a trademarks of Medinol Ltd.

PRESILLION(TM) /PRESILLION(TM) Plus are trademarks of Cordis Corporation.

Cordis Corporation a Johnson & Johnson company signed an exclusive
distribution agreement with Medinol in 2008 and is distributing the
PRESILLION(TM) Plus CoCr Coronary Stent on Rx System in Europe.

    Contact:

    Tamara Sugar
    Medinol Ltd
    E-mail: tamara@medinol.com
    +972-3-7679000
    Cellular: +972-52-4555545

    Vered Rahat-Roth
    Gitam Porter-Novelli
    e-mail: vered-r@gitam.co.il
    +972-52-8000380

.